|
|
Post by buyitonsale on Dec 11, 2019 16:24:16 GMT -5
yes, I calculated .2 of a decade  Let's see where the adoption is at that point. |
|
|
|
Post by robbmo on Dec 11, 2019 16:46:09 GMT -5
Hi, sorry, could someone tell me how to see the actual pricing in the CMED documents? I can't seem to find it. Thank you in advance.
|
|
|
|
Post by ktim on Dec 11, 2019 17:11:24 GMT -5
yes, I calculated .2 of a decade Let's see where the adoption is at that point. You got me! I tried wiping the spot off my screen  OMG, It was a decimal point. How many patients do you think Afrezza currently has in the US? |
|
|
|
Post by buyitonsale on Dec 11, 2019 17:23:41 GMT -5
I know all about patients in US.
How many doctors are willing to prescribe in US currently for various reasons, mostly of being afraid of a change and not willing to learn to help patients ?
How many people can't afford to pay for a best insulin option in US because insurers do not realize that a few thousand a year in insulin savings for them will be wiped out in a single ER visit or complications down the road ?
How many in US adopted CGMs ? When they do they will realize they have been duped since 2014...
Comparing Brazil and US adoption is not fair at this point, let's compare in 2 years.
|
|
|
|
Post by mytakeonit on Dec 11, 2019 18:15:31 GMT -5
Like I said before, International first then it takes off in the U.S. ... I mean we have to test new products on the rest of the world to be sure it's SAFE, before we let our citizens use Afrezza. But, until I buy a larger SAFE ... ahhh ... never mind.
But, that's mytakeonit
|
|
|
|
Post by wgreystone on Dec 11, 2019 18:15:32 GMT -5
I don’t think the object with Brazil is profit. In fact the lower the price as long as it is above break even on cost to produce the better imho as there is no way to make a reasonable profit and have it succeed. Higher price creates same problem as here, Afrezza becomes unavailable for too many who would otherwise use it. The goal here is to sell as much as mnkd can. The increase in production will lower average unit cost and increase profits as a result. And the more they sell in Brazil the more well known Afrezza will become in the rest of the world including here in the US. GLTAL’s!!!! Mike has said many times that Brazil was not going to be a huge profit center. He said it will help in utilizing their manufacturing facility while making a small profit. The only profitable market is the US. And don't expect a lot of profits out of India or China. Brazilians should write Thank-You letters to Mike. |
|
|
|
Post by mnkdfann on Dec 11, 2019 18:16:11 GMT -5
The FDA site says you can import 3 months of a legitimate drug at a time, but there are all sorts of restrictions. I'm not qualified to decipher it all. Someone else can do that. But my gut feeling is that bringing in a year's supply at a time could cause problems at Immigration / Customs. In which case you may get to keep nothing. And I'm sure bringing in large quantities of a white powder from Brazil will not raise any flags. I'm sure there are already many pharmaceuticals on the market in Brazil at prices much lower than what they are priced at in the States. Is it currently a thing for U.S. citizens to travel to Brazil to fill cheap prescriptions? Yes, but who decides what a "90 day supply" is? A diabetic prescription can't specify since the amount used varies each day, so a doctor could write for a 100 boxes and it could still be argued that it's a 90 day supply. Who decides? In this sort of case, I imagine it would be an underpaid under-trained government employee power-tripping at a customs / border crossing. Bring a doctor's note next time explicitly stating that it is a 90 day supply, they will tell you, as they confiscate the goods. |
|
|
|
Post by shawnonafrezza on Dec 11, 2019 18:34:06 GMT -5
The FDA site says you can import 3 months of a legitimate drug at a time, but there are all sorts of restrictions. I'm not qualified to decipher it all. Someone else can do that. But my gut feeling is that bringing in a year's supply at a time could cause problems at Immigration / Customs. In which case you may get to keep nothing. And I'm sure bringing in large quantities of a white powder from Brazil will not raise any flags. I'm sure there are already many pharmaceuticals on the market in Brazil at prices much lower than what they are priced at in the States. Is it currently a thing for U.S. citizens to travel to Brazil to fill cheap prescriptions?
Also interesting: kutv.com/news/local/utah-insurer-plans-to-send-patients-to-mexico-for-cheaper-medicine I wonder if they'd be willing to pay for airline tickets as well. Welcome to diabetes hell, it's a real problem. I use x units of insulin a day but I tell my endo I use 2x so the prescription gives me buffer. Many people do not know to do that and end up in sticky situations. |
|
|
|
Post by bababooey on Dec 12, 2019 1:34:29 GMT -5
So looks like Mannkind will be taking a huge net loss selling in Brazil. That’s great. And those people talking about flying to Brazil to get Afrezza, this will only cut into mankind’s bottom line.
|
|
|
|
Post by nylefty on Dec 12, 2019 1:42:40 GMT -5
So looks like Mannkind will be taking a huge net loss selling in Brazil. That’s great. And those people talking about flying to Brazil to get Afrezza, this will only cut into mankind’s bottom line. No, it doesn't look like MannKind will take a "huge net loss." Where did you get that idea? StockTwits? |
|
|
|
Post by mytakeonit on Dec 12, 2019 2:02:44 GMT -5
It's more like the end story of the paid short bashers ... What can I say? I'm surprised with the recent developments that any of these bashers are around. Just load up shares and watch ...
But, that's mytakeonit
|
|
|
|
Post by agedhippie on Dec 12, 2019 6:41:15 GMT -5
Welcome to diabetes hell, it's a real problem. I use x units of insulin a day but I tell my endo I use 2x so the prescription gives me buffer. Many people do not know to do that and end up in sticky situations. I once had a very annoying hour on the phone with a technician at Express Scripts who wanted to cut my prescription to the literal amount that was prescribed per dose. It took that long because I had to go through two more layers to get to a real pharmacist who understood the problem and issued the override. The prescription mentioned a number of pens, what I used, and a dose, because they need that apparently. That, and that they adjusted my 90 day Tresiba prescription to become a 63 day prescription so they could ship whole boxes. I also maintain a buffer to allow for insurance stupidity. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 12, 2019 12:27:15 GMT -5
So looks like Mannkind will be taking a huge net loss selling in Brazil. That’s great. And those people talking about flying to Brazil to get Afrezza, this will only cut into mankind’s bottom line. That's inaccurate. Brazil will be profitable but not as profitable as the US. Actually no one is as profitable as the US. Brazil will help the company better utilize their facility. Efficiency's will increase. |
|
|
|
Post by brianrocco on Dec 12, 2019 13:40:45 GMT -5
I think that the pricing was the last requirement; ANVISA approved the drug back in May. Most diabetics in Brazil get their insulin, which is supplied by government owned non-profit production centers, at the "Farmacia Popular" where the drugs are free. The trick is to get distribution in the pharmacies that are full service, for profit centers, and to get physicians to write scripts. I noted that there was no PMVG price announced which suggests the government will not be buying Afrezza for the Farmacia Popular. 8U X 90 70.63 ($17.14) 12U X 90 105.95 ($25.71) 4U X 60, 8U X 30 47.09 ($11.43) 4U X 30, 8U X 60 58.86 ($14.29) 8U X 60, 12U X 30 82.41 ($20.00) 4U X 90, 8U X 90 105.95 ($25.71) 1 Brazilian Real equals 0.24 United States Dollar ====================================================================================== The trick is to get distribution in the pharmacies that are full service, for profit centers, and to get physicians to write scripts. The trick is to get distribution on the Black Market for profit centers and physicians? |
|
|
|
Post by brianrocco on Dec 12, 2019 13:53:01 GMT -5
The prices quoted above are about $.02 per unit of Afrezza insulin, versus about $1.00 per unit of Afrezza insulin retail in the U.S. per GoodRx. If these Brazilian prices are accurate, and Mannkind is not taking a loss on selling to Brazil, then Mannkind manufacturing costs (at least marginal costs) are very, very low relative to net price. And if that is the case, why is Mannkind's gross margin so low? If the manufacturing cost per unit would drop precipitously with volume (lots of fixed cost and low marginal costs), Mannkind should cut prices and increase volume. Sales and gross margins would rise dramatically assuming that coverage by the the insurance companies and demand of uninsured diabetics is sensitive to a large reduction in price. I must be wrong somewhere above. Please advise where. Thanks.
|
|
